<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We examined the effects of <z:e sem="disease" ids="C0851834" disease_type="Disease or Syndrome" abbrv="">hyperglycemic conditions</z:e> on <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e> of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Angiotensin (A)-II increased growth, invasion, and anti-apoptotic survival in HT29 and CT26 cells </plain></SENT>
<SENT sid="2" pm="."><plain>In contrast, angiotensinogen (ATG) increased these features in HT29 cells but not in CT26 cells </plain></SENT>
<SENT sid="3" pm="."><plain>HT29 cells expressed A-II type 1 receptor, chymase, and rennin, whereas CT26 cells did not express renin </plain></SENT>
<SENT sid="4" pm="."><plain>Renin expression and ATG-induced cell growth, invasion, and survival induced and increased as <z:chebi fb="105" ids="17234">glucose</z:chebi> concentration increased in HT29 cells and also CT26 cells </plain></SENT>
<SENT sid="5" pm="."><plain>An inhibitor of renin or chymase abrogated A-II production in HT29 cells </plain></SENT>
<SENT sid="6" pm="."><plain>Reduction of hepatic ATG production by cholesterol-conjugated antisense S-oligodeoxynucleotide suppressed <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e> of HT29 cells </plain></SENT>
<SENT sid="7" pm="."><plain>An examination of 121 CRC patients showed that <z:mp ids='MP_0002055'>diabetes</z:mp> in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cases was associated with higher blood HbA1c, higher renin and A-II concentrations in the <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumors</z:e>, and higher incidence of <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e> than in nondiabetic cases </plain></SENT>
<SENT sid="8" pm="."><plain>These results suggest that <z:mp ids='MP_0002055'>diabetes</z:mp>-associated angiotensin activation enhances <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e> of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> and may therefore provide a possible target for antimetastatic therapy in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
</text></document>